hit counter
ABIOMED, Inc. (ABMD) Stock News Sentiment & Price - Sentifly
ABMD - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



ABIOMED, Inc. (ABMD)

USA
Medical Appliances & Equipment
NASDAQ
ABMD Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ABMD Latest news
Business Wire
Neutral
Two Large Studies Demonstrate Complete Revascularization with Impella Heart Pumps Improves Ejection Fraction and Long-Term Patient Outcomes
2021-11-04 08:05

ORLANDO, Fla.--(BUSINESS WIRE)--Two large studies demonstrate complete revascularization with Impella heart pumps improves ejection fraction and long-term patient outcomes.

Business Wire
Neutral
Impella Advances to Higher Level of Recommendation in Newest ESC Guidelines
2021-11-03 08:02

DANVERS, Mass.--(BUSINESS WIRE)--The 2021 ESC guidelines for treatment of acute heart failure patients elevate technology such as Impella to Class IIa ("should be considered").

Business Wire
Neutral
TCT 2021 to Highlight Improved Patient Outcomes with Impella's Small, Smart and Connected Technology
2021-11-01 07:58

DANVERS, Mass.--(BUSINESS WIRE)--TCT 2021 showcases data and clinical studies supporting the use of Impella heart pumps in high-risk PCI, cardiogenic shock and right heart failure.

Seeking Alpha
Neutral
Abiomed's (ABMD) CEO Mike Minogue on Q2 2022 Results - Earnings Call Transcript
2021-10-28 12:34

Abiomed's (ABMD) CEO Mike Minogue on Q2 2022 Results - Earnings Call Transcript

Zacks Investment Research
Positive
Abiomed (ABMD) Q2 Earnings Beat Estimates
2021-10-28 10:43

Abiomed (ABMD) delivered earnings and revenue surprises of 5.10% and -0.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research
Positive
Abiomed (ABMD) Beats on Q2 Earnings, Lowers FY22 Guidance
2021-10-28 10:42

Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.

Business Wire
Neutral
Abiomed Announces Q2 FY 2022 Revenue of $248 Million, Up 18% Year Over Year
2021-10-28 07:00

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces Q2 fiscal year 2022 revenue of $248 million, up 18% year over year.

Benzinga
Neutral
Abiomed's Earnings Outlook
2021-10-27 11:55

Abiomed (NASDAQ:ABMD) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement.

Zacks Investment Research
Positive
Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?
2021-10-22 12:48

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q2 sales.

Zacks Investment Research
Negative
Earnings Preview: Abiomed (ABMD) Q2 Earnings Expected to Decline
2021-10-21 17:24

Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Loading more news...